Lilly taps obesity windfall for more M&A. Plus, Elon Musk remarks pull GE Vernova lower

The weekend shock is less about immediate substitution and more about reinforcing a multi-quarter bottleneck premium in industrial power equipment. Even if a credible new entrant eventually internalizes blade casting, the qualification cycle in mission-critical components is long enough that incumbents should keep pricing power; the first-order loser is not today’s revenue, but the multiple if investors assume competitive erosion arrives faster than it can. In that sense, the selloff in GEV/HWM looks more like a sentiment event than a fundamental reset.

The bigger second-order risk for GEV is not the announced threat itself, but capital formation: higher oil plus a 10-year near 4.75% raises the hurdle rate for data-center, grid, and generation projects that underpin backlog growth. If financing conditions stay tight for 1-3 months, order timing can slip even without any change in end-demand, which would matter more than a single social-media headline. That makes GEV a good company but a less clean macro hedge than the market may think.

On obesity-drug coverage, the market is still treating employer coverage as a binary win/loss, but the more important mechanism is whether employers optimize for near-term pharmacy spend or longer-dated medical cost deflation. The consensus may be underestimating how sticky the latter is, which supports LLY’s category power over 6-18 months; however, there is no obvious direct equity trade in PEP from one benefits decision. The more interesting watch item is whether peers follow, which would pressure payer negotiations and amplify pricing scrutiny on GLP-1s into year-end.